William Blair Investment Management LLC Takes $21.37 Million Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• William Blair Investment Management acquired 258,173 ANI Pharmaceuticals shares worth approximately $21.37 million, representing about 1.13% of the company. Institutional investors and hedge funds collectively own 76.05% of ANIP.
• Analyst sentiment remains positive but has softened: the stock carries a “Moderate Buy” consensus rating and an average price target of $105.83, while several firms recently lowered ratings or price targets.
• ANI Pharmaceuticals beat quarterly expectations, reporting $2.21 in EPS and $266.04 million in revenue, up 25.8% year over year. Shares opened at $75.35, near the lower end of their 52-week range of $70.15 to $99.50.

William Blair Investment Management LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 258,173 shares of the specialty pharmaceutical company's stock, valued at approximately $21,372,000. William Blair Investment Management LLC owned approximately 1.13% of ANI Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of ANIP. Advisors Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals in the first quarter worth $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock worth $736,000 after purchasing an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock worth $3,235,000 after purchasing an additional 423 shares during the period. Jane Street Group LLC acquired a new stake in ANI Pharmaceuticals during the first quarter worth about $2,706,000. Finally, Norges Bank acquired a new stake in ANI Pharmaceuticals during the second quarter worth about $625,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the sale, the senior vice president owned 75,534 shares in the company, valued at $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Thomas Haughey sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares in the company, valued at $3,144,452.64. This represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 18,987 shares of company stock valued at $1,546,405. Company insiders own 8.10% of the company's stock.

Analysts Set New Price Targets

ANIP has been the topic of several recent analyst reports. Weiss Ratings lowered shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a report on Monday, August 10th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Guggenheim decreased their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $105.83.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $75.35 on Friday. The stock's 50-day simple moving average is $80.36 and its 200 day simple moving average is $78.88. The firm has a market capitalization of $1.73 billion, a PE ratio of 16.24 and a beta of 0.44. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a twelve month low of $70.15 and a twelve month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business's quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source